An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)
An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)
The purpose of this study is to determine changes on overall gait as well as in multiple gait
 and balance parameters after withdrawal of dalfampridine-ER 10mg in MS subjects who are
 receiving the medication consistently for at least two weeks prior to screening.
Longitudinal study design
Inclusion Criteria:

 -  Diagnosis of multiple sclerosis

 -  Receiving Ampyra® consistently for at least 2 weeks prior to the screening visit

 -  No history of seizures except simple febrile seizures

 Exclusion Criteria:

 -  Sexually active woman of childbearing potential who is not surgically sterile, <two
 years post-menopause or is not using effective birth control methods

 -  Subject who is pregnant or breastfeeding